Tau hyperphosphorylation has been considered a major contributor to neurodegeneration in Alzheimer’s disease (AD) and frontotemporal dementia, and related tauopathies have gained prominence in the development of therapies for these conditions. Here, MAPT is linked to Alzheimer disease.